Overview

Subcutaneous Pharmacokinetics of Belatacept

Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
Pharmacokinetics, Bioavailability, Safety and Immunogenicity of Single Doses of Belatacept Administered Subcutaneously to Healthy Subjects
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Abatacept